UCSF Brain Tumor Center Clinical Trials
Our clinical trials evaluate a broad range of innovative therapies for both adults and children with brain tumors.
- Recruiting
- Pediatrics
- On Hold
Conditions
Atypical Teratoid / Rhaboid Tumor (AT/RT)
Chordoma
The purpose of this Phase I clinical trial is to evaluate the safety and dosage of tazemetostat in treating children and young adults with relapsed or refractory tumors, including AT/RT and chordoma.
Conditions
Glioma
Astrocytoma
Anaplastic astrocytoma (grade III)
Glioblastoma (grade IV)
DCC-2618 is an orally administered drug designed to inhibit the activity of proteins called KIT and PDGFRα. KIT and PDGFRα are proteins that are mutated or abnormally active in variety of cancer cell types; when mutated, these proteins can increase tumor cell proliferation and resistance to chemotherapy.
Conditions
Glioma
Astrocytoma
Glioblastoma (grade IV)
This clinical trial will evaluate the safety, efficacy and clinical activity of BGB-290 in combination with radiation therapy and/or temozolomide (TMZ), for treating patients with newly diagnosed or recurrent glioblastoma.
Conditions
Glioma
Astrocytoma
Pleomorphic xanthoastrocytoma (grades II-III)
Pilocytic astrocytoma (grade I)
Brainstem Glioma
Diffuse Midline Glioma
Atypical Teratoid / Rhaboid Tumor (AT/RT)
Ependymoma
Medulloblastoma
Summary
The purpose of this Phase I/II clinical trial is to evaluate the dosage, safety and efficacy of pembrolizumab in treating pediatric participants with any of the following types of cancer:
Conditions
Glioma
Astrocytoma
Pleomorphic xanthoastrocytoma (grades II-III)
Pilocytic astrocytoma (grade I)
Brainstem Glioma
Diffuse Midline Glioma
Atypical Teratoid / Rhaboid Tumor (AT/RT)
Subependymal giant cell astrocytoma (grade I)
Medulloblastoma
Choroid Plexus Tumors
The purpose of this Phase I clinical trial is to evaluate the safety and efficacy of the drug ramucirumab, in treating children with recurrent or refractory solid tumors, including CNS tumors.
Conditions
Glioma
Astrocytoma
Diffuse astrocytoma (grade II)
Oligodendroglioma
This clinical trial evaluates the safety and feasibility of IMA950 (a vaccine-based immunotherapy) in combination with varlilumab (an antibody-based immunotherapy) in patients with newly diagnosed or recurrent low-grade glioma (grade II).
Conditions
Glioma
Astrocytoma
Glioblastoma (grade IV)
This phase III, randomized, double-blinded, placebo-controlled clinical trial evaluates the efficacy of nivolumab (an immunotherapy drug) in combination with temozolomide and radiation therapy, for treating patients with newly diagnosed glioblastoma.
Conditions
Glioma
Astrocytoma
Glioblastoma (grade IV)
The purpose of this study is to evaluate the safety and efficacy of the combination of Avelumab and re-irradiation therapy, for patients with IDH mutant gliomas that have transformed to glioblastoma after chemotherapy.
Conditions
Glioma
Astrocytoma
Diffuse Midline Glioma
Brainstem Glioma
This Phase I clinical trial will assess the safety and preliminary efficacy of delivering nal-IRI (a specialized formulation of irinotecan, a chemotherapy drug) directly into the brain through convection enhanced delivery, in treating children with newly diagnosed DIPG.
Conditions
Glioma
Astrocytoma
Glioblastoma (grade IV)
This clinical trial will evaluate the efficacy of MDNA55 in treating patients with recurrent glioblastoma. MDNA55 will be administered during a minimally invasive surgery, using convection-enhanced delivery.
Conditions
Glioma
Astrocytoma
Pleomorphic xanthoastrocytoma (grades II-III)
Pilocytic astrocytoma (grade I)
Brainstem Glioma
Diffuse Midline Glioma
Atypical Teratoid / Rhaboid Tumor (AT/RT)
Subependymal giant cell astrocytoma (grade I)
Choroid Plexus Tumors
Medulloblastoma
The purpose of this Phase I clinical trial is to study the side effects and best dose of entinostat in treating pediatric patients with recurrent or refractory solid tumors.
Conditions
Glioma
Oligodendroglioma
Astrocytoma
Diffuse astrocytoma (grade II)
The purpose of this study is to investigate the effect of a drug called everolimus (RAD001, or Afinitor) alone or in combination with temozolomide (a chemotherapy drug) in treating patients with newly diagnosed low-grade glioma.